2nd National Conference Human Retroviruses and Related Infections Washington, DC - January 29 - February 2, 1995

Natl Conf Hum Retrovir Relat Infect 1995 Jan 29-Feb 2;2: (abstract no. 3)

Maenza JR, Keruly JC, Moore RD, Chaisson RE, Gallant JE
Johns Hopkins University School of Medicine, Baltimore, MD

OBJECTIVES: To identify risk factors for the development of FRC in HIV-infected patients.

METHODS: Paired case-control study. Cases (ca) (n=25) with clinical and microbiologic FRC compared with controls (Co) (n=25) matched for time of first diagnosis of oroesophageal candidiasis and for followup time.

RESULTS: Following their first episode of candidiasis, patients who developed FRC had more treated episodes of candidiasis (medians(med): Ca 3, Co 2, p=0.003); lower CD4 counts (Ca 74±80, Co 240±251, p=0.007); greater duration of all antifungal therapy (med: ca 519 days, Co 127, p=0.003) and of azole therapy (med: Ca 272 days, Co 14, p=0.003) and a larger fraction of time on azoles (med: Ca 56%, Co 296, p=0.0002), even considering only time from first azole use (med: Ca 74%, Co 22%, p=0.008). There were no significant differences for clinical stage of HIV at initial assessment, HIV risk behavior, use of antiretroviral therapy, duration of topical therapy for thrush, or site of Candida infection (oral/esophageal).

CONCLUSIONS: Compared to patients with susceptible candidiasis, patients who develop FRC have more advanced HIV disease and greater exposure to oral azoles, Relatives importance of disease severity and azole exposure is not yet known.

Keywords: AIDS Vaccines, Acquired Immunodeficiency Syndrome, Azoles, CD4 Lymphocyte Count, Candidiasis, Candidiasis, Oral, Case-Control Studies, Clotrimazole, Fluconazole, HIV Infections, HIV Seropositivity, Humans, Itraconazole, Risk Factors

1995-01-29
3

Copyright © 1995 - The American Society for Microbiology. Reproduction of this abstract (other than one copy for personal reference) must be cleared through the American Society for Microbiology.